Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Myscape: Myeloma single cell atlas for precision exploration reveals stage-specific T cell dysregulation associated with progression and therapy

Siddhartha Mantrala, Hope Mumme, William Pilcher et al. Nov 03, 2025 pp. 2180-2180 10.1182/blood-2025-2180

Abstract Background Multiple myeloma (MM) is a hematological malignancy originating in the bone marrow, characterized by...

CD132 expression promotes AML aggressiveness via the JAK-STAT signaling pathway

Yiyang Ding, Luhan Deng, Xunhong Cao et al. Nov 03, 2025 pp. 3481-3481 10.1182/blood-2025-3481

Abstract Acute myeloid leukemia (AML) is a common and challenging leukemia in adults, often accompanied by a poor prognosis. Despite the ava...

Integrated single-cell RNA sequencing and TCR profiling identifies immune drivers of severe early toxicity in CLL patients treated with idelalisib

Saurabh Yadav, Lu Yang, Zunqiu Wang et al. Nov 03, 2025 pp. 2103-2103 10.1182/blood-2025-2103

Abstract PI3K inhibitors, such as idelalisib and duvelisib, have demonstrated efficacy in relapsed/refractory chronic lymphocytic leukemia (...

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Binod Dhakal, Shinsuke Iida, M Hasib Sidiqi et al. Nov 03, 2025 pp. 2215-2215 10.1182/blood-2025-2215

Abstract Introduction: Effective tumor burden reduction using bridging therapy has been shown to correlate with better progression-free surv...

MALT1 inhibitor suppresses AML by inducing MCPIP1 expression and shows synergy with venetoclax

Weiguang Cui, Liyuan Li, Nan Zhou et al. Nov 03, 2025 pp. 6807-6807 10.1182/blood-2025-6807

Abstract Background Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Over the last decade, the overall survival of...

Pregnancy outcomes in alpha thalassemia major: A population-based analysis using the national inpatient sample 2017-2022

Benedict Amalraj, Mariana Marrero Castillo, Anil Ananthaneni Nov 03, 2025 pp. 4691-4691 10.1182/blood-2025-4691

Abstract Introduction: Clinically significant alpha thalassemia, encompassing Hemoglobin H (HbH) disease and alpha thalassemia major, consti...

High-throughput oxygen dissociation assay enables rapid screening of hemoglobin oxygen affinity modifying therapies

Zoe Sekyonda, William Wulftange, Ozan Akkus et al. Nov 03, 2025 pp. 6493-6493 10.1182/blood-2025-6493

Abstract Introduction The oxygen dissociation curve (ODC) quantitatively describes the affinity of hemoglobin (Hb) to bind and release oxyge...

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Sonia More', Massimo Offidani, Laura Corvatta et al. Nov 03, 2025 pp. 4002-4002 10.1182/blood-2025-4002

Abstract Introduction. The recent introduction of novel therapies, such as anti-CD38 monoclonal antibodies, into the therapeutic landscape of...

Plasmacytoid dendritic cells (PDCs) signatures from integrated profiling predict AML prognosis and treatment response

Xuan Wen, Minming Li, Chengxin Deng et al. Nov 03, 2025 pp. 7040-7040 10.1182/blood-2025-7040

Abstract Background: Acute myeloid leukemia (AML) is a highly aggressive and heterogeneous hematologic malignancy. Despite advances in preci...

Safety and efficacy of autologous hematopoietic stem cell transplantation followed by CAR-T therapy in patients with high-risk or advanced plasma cell neoplasms

Yi Wang, Yanli Feng, Wei Zhou et al. Nov 03, 2025 pp. 2298-2298 10.1182/blood-2025-2298

Abstract Introduction Autologous hematopoietic stem cell transplantation (auto-HSCT) remains an important strategy for prolonging survival i...

Therapeutic targeting of sphingosine-1-phosphate receptor 1 (S1PR1) in angioimmunoblastic T-cell lymphoma.

Ruth Alonso Alonso, Anouchka Laurent, José Rodriguez Cortés et al. Nov 03, 2025 pp. 459-459 10.1182/blood-2025-459

Abstract Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive subtype of peripheral T-cell lymphoma (PTCL) derived from malignant tran...

Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML

Rumeng Li, Qingmei Han, Tian Zeng et al. Nov 03, 2025 pp. 7270-7270 10.1182/blood-2025-7270

Abstract Background: In patients with myeloproliferative neoplasms (MPNs), an increased blast percentage or progression to secondary acute m...

Patient assistance for drug cost sharing: Highlighting the variability across pharmaceutical manufacturers of specialty oral anticancer medications for blood cancers

Anoosha Shukla, John Lin, Pengxiang Li et al. Nov 03, 2025 pp. 7932-7932 10.1182/blood-2025-7932

Abstract Background: Although specialty oral anticancer medications (SOAMs) have improved outcomes for patients with blood cancers, patients...

Clinical outcomes of adenovirus infection in allogeneic hematopoietic cell transplant recipients: A real-world propensity-matched analysis

Abid Nawaz Khan Adil, Aakriti Adhikari, abdulwali khan et al. Nov 03, 2025 pp. 5990-5990 10.1182/blood-2025-5990

Abstract Background: Adenovirus infection is a known complication following allogeneic hematopoietic stem cell transplan...

Use of thrombopoietin receptor agonists for thrombocytopenia in pediatric malignancies: A retrospective cohort study

Anna Elias, Ahmad Al-Huniti, Catherine Martin et al. Nov 03, 2025 pp. 1269-1269 10.1182/blood-2025-1269

Abstract Background: Thrombocytopenia is a common and clinically significant complication in pediatric patients undergoi...

The genomic differences in hispanic vs non hispanic patients with primary central nervous system lymphoma

Supreet Kaur, Abhishek Pandya, Xiaojing Wang et al. Nov 03, 2025 pp. 7070-7070 10.1182/blood-2025-7070

Abstract Introduction: Primary Central Nervous system lymphomas (PCNSL) account for ~ 4% of newly diagnosed CNS tumors with an annual incide...

Efficacy and safety of romiplostim N01 in cancer treatment–induced thrombocytopenia: Results from a phase II off-label study in China

Yu Zhang, Qijia Zheng, Nanxi Dong et al. Nov 03, 2025 pp. 4806-4806 10.1182/blood-2025-4806

Abstract Cancer Treatment-induced Thrombocytopenia (CTIT) is a common adverse event during cancer therapy, contributing to treatment delays,...

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Andrew Kuykendall, Aniket Bankar, Kristen Pettit et al. Nov 03, 2025 pp. 81-81 10.1182/blood-2025-81

Abstract Background: Rusfertide is a weekly, self-administered, subcutaneously injected first-in-class hepcidin mimetic. Previously, we pres...

From lab to field: Evaluation of a rapid, low-cost, point-of-care ferritin assay for detection of iron deficiency

Vivian Uzoechi, Priyaleela Thota, Lisbel Gonzalez et al. Nov 03, 2025 pp. 599-599 10.1182/blood-2025-599

Abstract Background: Iron deficiency (ID) is among the most common global hematologic disorders and a leading contributor to the global dise...

Impact of clonal hematopoiesis on hematologic recovery and outcomes following tumor-infiltrating lymphocyte therapy

Zhuoer Xie, Surendra Neupane, Joshua Traina et al. Nov 03, 2025 pp. 5932-5932 10.1182/blood-2025-5932

Abstract Introduction: Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a biomarker of adverse outc...

Clinical and economic burden of steroids in primary immune thrombocytopenia: A real-world italian analysis

Diletta Valsecchi, Giuseppe Carli, Roberta Bini et al. Nov 03, 2025 pp. 4466-4466 10.1182/blood-2025-4466

Abstract Introduction: Primary Immune Thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count and increased b...

Influenza vaccine coverage, effectiveness, and disease burden among pediatric sickle cell patients in Connecticut from 2021-2024: A test-negative case-control study

Precious Nchekwube, Hillary Kuzaro, Elizabeth Cohen et al. Nov 03, 2025 pp. 4745-4745 10.1182/blood-2025-4745

Abstract Background: Children with sickle cell disease (SCD) are at high risk of influenza-related morbidity and mortality. They are more li...

ApoB-100 and apo(a) levels in healthy blood donors by ABO blood type.

Maya Rodriguez, Wen Dai, Nina Yang et al. Nov 03, 2025 pp. 6692-6692 10.1182/blood-2025-6692

Abstract Introduction: ABO blood types have been shown to associate with the incidence of thrombotic vascular diseases. A, B and AB blood ty...

Chronological age predicts suboptimal multiple myeloma treatment independent of frailty and socioenvironmental factors: A retrospective multi-center cohort study

Maya Abdallah, June Corrigan, John Culnan et al. Nov 03, 2025 pp. 2808-2808 10.1182/blood-2025-2808

Abstract Background: Multiple myeloma (MM) is the second most common hematologic malignancy in the United States, with a median age at diagn...

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Susan Branford, Ali Albeer, Ángela Villaverde Ramiro et al. Nov 03, 2025 pp. 75-75 10.1182/blood-2025-75

Abstract Background Evidence has accumulated that somatic mutations in myeloid genes other than BCR::ABL1 at CML diagnosis are associated wi...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page